Accupro

quinapril hydrochloride

Accupril, Accupro, (UK) Quinil (UK)

Pharmacologic class: Angiotensin-converting enzyme (ACE) inhibitor

Therapeutic class: Antihypertensive

Pregnancy risk category D

Action

Inhibits conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; decreases cardiac output. Increases plasma renin levels and reduces aldosterone levels, causing systemic vasodilation.

Availability

Tablets: 5 mg, 10 mg, 20 mg, 40 mg

Indications and dosages

Hypertension

Adults: Initially, 10 to 20 mg P.O. daily for patients not receiving diuretics, with subsequent dosages adjusted at 2-week intervals according to blood pressure response at peak (2 to 6 hours) and trough (predose) blood levels; for maintenance, 20 to 80 mg/day as a single dose or in two divided doses. In patients receiving diuretics, discontinue diuretic 2 to 3 days before starting quinapril; if blood pressure isn't controlled, resume diuretic. If diuretic can't be discontinued, start therapy with 5 mg/day quinapril.

Adjunct in heart failure

Adults: Initially, 5 mg P.O. b.i.d., titrated weekly until effective dosage is determined. For maintenance, 20 to 40 mg/day in two evenly divided doses.

Dosage adjustment

• Renal impairment
• Elderly patients

Off-label uses

• Aortic insufficiency
• Atherosclerosis
• Postoperative hypertension
• Myocardial infarction
• Diabetic or nondiabetic neuropathy

Contraindications

• Hypersensitivity to drug or other ACE inhibitors
• Angioedema caused by other ACE inhibitors

Precautions

Use cautiously in:
• autoimmune diseases, aortic stenosis, renal artery stenosis, hypertrophic cardiomyopathy, cerebrovascular or cardiac insufficiency, collagen vascular disease, hepatic or renal impairment, hypovolemia, hyponatremia, hypotension, neutropenia, chronic cough, proteinuria, febrile illness
• family history of angioedema
• risk factors for development of hyperkalemia, including renal insufficiency, diabetes mellitus, concurrent use of potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes
• concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) in patients who are elderly, volume-depleted (including those on diuretics), or with compromised renal function
• concurrent immunosuppressant, lithium, or diuretic therapy
• black patients
• elderly patients
• pregnant or breastfeeding patients
• children (safety not established).

Administration

• Administer with or without food, but not with high-fat meal.
• Know that if quinapril alone doesn't adequately control blood pressure, a diuretic may be added.

Adverse reactions

CNS: dizziness, drowsiness, fatigue, headache, insomnia, depression, vertigo, paresthesia, asthenia, malaise, nervousness, syncope

CV: hypotension, angina pectoris, palpitations, chest pain, tachycardia, arrhythmias

EENT: amblyopia, sinusitis, pharyngitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, dry mouth

GU: erectile dysfunction

Metabolic: hyperkalemia

Musculoskeletal: back pain

Respiratory: cough, dyspnea

Skin: rash, pruritus, alopecia, flushing, diaphoresis, photosensitivity

Other: taste disturbances, fever, viral infections, hypersensitivity reactions including anaphylaxis

Interactions

Drug-drug.

Diuretics, other antihypertensives: increased hypotension

Gold (sodium aurothiomalate): increased risk of rare nitritoid reactions (including facial flushing, nausea, vomiting, and hypotension)

Lithium: increased serum lithium level and lithium toxicity

NSAIDs: may result in deterioration of renal function, including acute renal failure and attenuated ACE inhibitor antihypertensive effect

Potassium-sparing diuretics, potassium supplements: increased risk of hyperkalemia

Tetracyclines: decreased tetracycline absorption

Drug-diagnostic tests.Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, potassium: increased levels

Drug-food.High-fat foods: decreased rate and extent of drug absorption

Salt substitutes containing potassium: increased risk of hyperkalemia

Patient monitoring

• Monitor vital signs and cardiovascular status. Be sure to ask patient if he's experiencing angina.
• Assess CBC and liver function tests.
• Monitor potassium level. Watch for evidence of hyperkalemia.

Watch closely for signs and symptoms of angioedema, especially in black patients after first dose.
• Assess for dry, nonproductive cough and signs and symptoms of infection.
• Monitor renal function periodically in patients receiving concurrent NSAID therapy.

Patient teaching

• Tell patient he may take with or with­out food, but not with high-fat meal.

Advise patient to immediately report facial or tongue swelling or difficulty breathing.
• Instruct patient to monitor and record his blood pressure.
• Tell patient to promptly report dry, nonproductive cough and signs and symptoms of infection.
• Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
• Tell patient that excessive fluid loss (as from sweating, vomiting, or diarrhea) and inadequate fluid intake increase the risk of light-headedness (especially in hot weather).
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Advise patient to avoid salt substitutes containing potassium.
• Tell female patient to notify prescriber of possible pregnancy. Caution her not to breastfeed.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

Accupro

A brand name for QUINAPRIL.
References in periodicals archive ?
NYSE: MSM), a leading distributor of Metalworking and Maintenance, Repair and Operations ("MRO") products and services to industrial customers throughout North America, is expanding its Accupro portfolio of high-performance metalworking products for small, precise applications.
They recognize the precision, high performance and value the Accupro brand offers, and we are excited to deliver an enhanced suite of products that are designed specifically to help address our customers' unique needs.
The die is available for up to 11 layers and can be outfitted with IBC hardware and Macro's Accupro automatic gauge-control die-lip heaters.
Extrusion blow molds; foam molds Macro Engineering & ACCUPRO automatic gauge control system for blown Technology Inc.
Sinclair and Accupro offer several excellent designs, and Sinclair will actually advise you on what size patch to use with what size jag.
Marshall & Swift's AccuPro software program is touted as saving as much as 15% of restoration costs in indemnity dollars, said Peter Wells, senior vice president of the Princeton, N.
28, 2013 /PRNewswire/ -- AccuPro Business Solutions, LLC (AccuPro) today announced a strategic partnership with AB Systems, the highest ranking nationwide network of over 1500 offices specializing in revenue cycle solutions, practice management, and private practice business support throughout the United States.
Delica, Owner & President at AccuPro Business Solutions, LLC.
First showing of recently introduced Accupro auto-die for gauge control, using an 8-in.
Macro Engineering introduced its AccuPro die for automatic gauging this year and has built five units for European, Korean, and Canadian customers.
teams its Accupro die with auto-tuning software and a 360[degrees] oscillating gamma-backscatter gauge from NDC Infrared Engineering of Irwindale, Calif.
Accupro USA Div Of RTI Research LTD 7/11 Box 2270 Blaine WA 98231-2270 Ship: 936 Peace Portal Drive #163, Blaine, WA 98231 604-888-7944 800-622-1366 604-882-6943 Fax ken@rtiresearchltd.